PIK3CA gene mutations make HER2- and hormone receptor-positive breast cancers treatment-resistant

Share :
Published: 16 Dec 2013
Views: 3437
Prof Sibylle Loibl - German Breast Group, Neu-Isenburg, Germany

Women with breast cancer characterised by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented at the 2013 San Antonio Breast Cancer Symposium ( SABCS ).


Read more here